Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 69452-0361
What is NDC 69452-0361?
NDC 69452-0361 refers to a specific pharmaceutical product marketed in the United States. Based on publicly available sources, it is identified as Vortioxetine (brand: Trintellix), an antidepressant used primarily for major depressive disorder (MDD). It was approved by the FDA in 2013 and is marketed by Takeda Pharmaceuticals.
Market Landscape Overview
Market Size and Adoption
The global antidepressant market was valued at approximately $16 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 2-3% through 2030. In the US, antidepressant prescriptions count for roughly 40 million annually, with newer agents like vortioxetine representing an increasing share of prescriptions due to perceived improved efficacy and tolerability.
Competitive Position
Vortioxetine competes mainly with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Key competitors include:
- Sertraline (Zoloft)
- Escitalopram (Lexapro)
- Venlafaxine (Effexor)
- Duloxetine (Cymbalta)
Vortioxetine’s differentiator involves its multimodal activity and lower rates of sexual dysfunction and weight gain, which influence prescribing trends.
Market Penetration and Utilization Trends
Approximately 10-15% of MDD patients switch to or are prescribed vortioxetine over traditional SSRIs or SNRIs. Its niche lies in treatment-resistant cases or patients intolerant to other antidepressants.
Pricing and Reimbursement
Vortioxetine's wholesale acquisition cost (WAC) in 2022 ranged between $700 and $800 per month. Payer reimbursement varies based on formulary placement; it is often preferred as a second-line agent due to its clinical profile.
Price Projections
Current Pricing Trends
- Wholesale acquisition cost (WAC): ~$750/month (as of 2022-2023)
- Average commercial insurance reimbursement: ~$700/month
- Out-of-pocket cost for patients: $50-$100/month with insurance, higher without
Projected Price Trajectory (Next 3-5 Years)
- Slight decreases in WAC expected due to increased generic competition starting around 2028.
- Biosimilar or alternative agents may enter the market, pressuring prices downward.
- Payers may negotiate further discounts or shift formulary access, leading to retail price reductions of 10-15% over 5 years.
Impact of Patent Expiry and Generics
Vortioxetine's patent expiration is anticipated around 2028-2030. Once generics enter, prices could drop by 40-60%. Early generic filings and market entry could occur 1-2 years prior to patent expiry, further decreasing costs.
Potential for Value-Based Pricing
Given its clinical profile, payers might offer higher reimbursement premiums for vortioxetine if recent comparative effectiveness studies favor it, potentially stabilizing or increasing prices in specialized formularies.
Regulatory and Policy Considerations
- FDA approval has been stable since initial approval.
- There are no current patent litigations or exclusivities beyond the existing patent protection until 2028-2030.
- The current U.S. administration focuses on lowering drug costs, which might accelerate generic approval processes and influence market prices.
Summary of Key Data Points
| Data Point |
Value |
Source |
| Market Size (2022) |
~$16 billion |
MarketWatch [1] |
| Prescription Volume (US) |
~40 million/year |
IQVIA [2] |
| Current WAC |
~$750/month |
GoodRx [3] |
| Patent Expiry |
2028-2030 |
FDA Orange Book [4] |
| Expected Price Reduction Post-Generic Entry |
40-60% |
Market trends |
Key Takeaways
- NDC 69452-0361 (vortioxetine) is a branded antidepressant with moderate market share compared to SSRIs.
- Its pricing has remained stable but is likely to decline post-generic entry starting around 2028.
- The market is competitive, with increasing pressure from generics and biosimilars.
- Price projections suggest a 10-15% decline over five years, accelerating significantly after patent expiration.
- Future value may hinge on clinical positioning and formulary negotiations, influencing price stability.
FAQs
Q1: When will generics for vortioxetine likely enter the market?
A1: Patent expiration is projected between 2028 and 2030, with generic filings possibly occurring 1-2 years prior.
Q2: How does vortioxetine compare price-wise to other antidepressants?
A2: It is more expensive than older SSRIs like sertraline or escitalopram, with WAC around $750/month versus ~$60/month for generics.
Q3: What factors could disrupt the current price projections?
A3: Accelerated approval of biosimilars or generics, payer negotiating leverage, and new clinical data favoring alternative treatments.
Q4: Are there formulations or indications beyond depression that affect pricing?
A4: Currently, vortioxetine is approved mainly for MDD; additional indications could influence market dynamics but are not imminent.
Q5: How do policy changes impact drug pricing?
A5: Legislation aimed at reducing drug costs, such as importation or compulsory licensing, could lead to faster price decreases.
Sources
[1] MarketWatch: Antidepressant Market Size 2022.
[2] IQVIA: Prescription Data, US.
[3] GoodRx: Current drug pricing.
[4] FDA Orange Book: Patent data.
